Highlights

  • Pfizer (NYSE: PFE) share price declined around 3.4% on December 16, 2025, following a reduced 2025 revenue forecast.
  • The company now anticipates approximately USD62 billion in 2025 revenue with flat sales expected into 2026 amid softer COVID-19 product demand.
  • Healthcare sector pressure contributed to broader stock market movements, with declines in related pharmaceuticals.

On December 16, 2025, shares of Pfizer Inc (NYSE:PFE), a global biopharmaceutical company, declined around 3.4% to close at USD 25.53, following the release of updated financial expectations for 2025 and guidance into 2026. The revised outlook includes a lower anticipated revenue figure for 2025, attributed largely to weaker sales in key product lines such as COVID-19 vaccines and treatments.

According to the latest reports, Pfizer now expects approximately USD62 billion in revenue for 2025, down from earlier guidance that spanned a range of USD61 billion to USD64 billion. Alongside this figure, the company reaffirmed its adjusted earnings per share outlook for the year.

Market reaction on the trading session reflected these updates, with Pfizer’s stock price finishing lower by around 3.4% compared with the prior session’s close. Trading volume on that day exceeded the recent average, indicating active market engagement with the news.

Outlook into 2026 and Broader Sector Movement

For the 2026 fiscal year, Pfizer projected relatively flat revenue growth, with expected sales between USD59.5 billion and USD62.5 billion. The company also outlined adjusted earnings per share estimates slightly below some market expectations, reflecting anticipated reductions in revenue from products nearing patent expirations and continued decreases in COVID-19 related sales.

In related market activity on December 16, several healthcare stocks, including names such as Merck and Johnson & Johnson, also experienced downward price movement as part of broader sector trends.

Economic and Market Context

The session in which Pfizer’s stock fell came amid broader U.S. market dynamics that included mixed movements across major indexes and varying economic indicators. Other factors such as employment data releases and commodity price shifts contributed to the overall trading environment.

While Pfizer’s latest guidance reflects transitional challenges as demand for COVID-19 products continues to wane, the company has emphasized ongoing research and development efforts across multiple therapeutic areas as part of its long-term operations.